抗 PD-1/PD-L1 抑制剂治疗的挑战：超进展，潜在机制和应对策略。
Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.
机构信息
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
出版信息
Biomed Pharmacother. 2022 Jun;150:112949. doi: 10.1016/j.biopha.2022.112949. Epub 2022 Apr 18.
Immunotherapy is now a mainstay in cancer treatments. Programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have opened up a new venue of advanced cancer immunotherapy. However, hyperprogressive disease (HPD) induced by PD-1/PD-L1 inhibitors caused a significant decrease in the overall survival (OS) of the patients, which compromise the efficacy of PD-1/PD-L1 inhibitors. Therefore, HPD has become an urgent issue to be addressed in the clinical uses of PD-1/PD-L1 inhibitors. The mechanisms of HPD remain unclear, and possible predictive factors of HPD are not well understood. In this review, we summarized the potential mechanisms of HPD and coping strategies that can effectively reduce the occurrence and development of HPD.
免疫疗法现已成为癌症治疗的主要方法之一。程序性细胞死亡 1（PD-1）/程序性细胞死亡配体 1（PD-L1）免疫检查点抑制剂（ICI）治疗为晚期癌症免疫治疗开辟了新途径。然而，PD-1/PD-L1 抑制剂引起的超进展性疾病（HPD）导致患者的总生存期（OS）显著下降，从而降低了 PD-1/PD-L1 抑制剂的疗效。因此，HPD 已成为 PD-1/PD-L1 抑制剂临床应用中亟待解决的问题。HPD 的机制尚不清楚，HPD 的可能预测因素也不明确。在这篇综述中，我们总结了 HPD 的潜在机制和应对策略，这些策略可以有效地减少 HPD 的发生和发展。
Zotero 插件